摘要
目的:研究促红细胞生成素对慢性心衰患者血栓风险的影响。方法:43例慢性心力衰竭合并轻度贫血的患者,随机分为2组:促红细胞生成素(EPO)组(22例)及对照组(21例)。EPO组患者给予多糖铁复合物胶囊150mg,2次/d加EPO每周10000～15000U。对照组患者给予多糖铁复合物胶囊150mg,2次/d。血红蛋白目标值为135g/L,疗程为3个月。治疗3个月后,用ELISA法测定4种血栓分子标志物浓度,包括凝血酶-抗凝血酶Ⅲ复合物(TAT)、凝血酶原片段1+2(F1+2)、D-二聚体(D-D)、纤溶酶-抗纤溶酶复合物(PAP)。结果:EPO组治疗前后以及EPO组和对照组治疗后,4种血栓分子标志物的比较差异均无统计学意义(P均>0.05)。结论:慢性心力衰竭患者接受EPO每周10000～15000U治疗未明显增加潜在血栓风险。
Objective： To study on the effects of erythropoietin on risk of thrombus in patients with chronic heart failure. Methods： Forty-three patients with chronic heart failure and mild anemia were divided randomizely into two groups： erythropoietin （EPO） group （22 cases） and control group （21 cases）. The patients in the EPO group were administered with polysaccharide-iron complex 150 mg two times daily plus erythropoietin 10 000-15 000 U weekly. The patients in the control group were administered with polysaceharide-iron complex 150 mg two times daily. The target haemoglobin concentration was 135 g/L, and the duration of therapy was 3 months. The plasma levels of four thrombus molecular markers including thrombin-antithrombin Ⅲ complex （TAT）, prothrombin fragments 1 and 2 （F1＋2）, D-dimer （D-D）, and plasmin-antiplasmin complex （PAP） were measured with ELISA method after 3 months treatment. Results： There were not significant differences in four thrombus molecular markers before and after treattment in the EPO group, and after treatment between the EPO group and control group （all P 〉 0.05）. Conclusion： The potential risk of thrombus is not obviously increased in patrents with chronic heart failure treated with erythroietin 10 000- 15 000 U weekly.
出处
《药物不良反应杂志》
2007年第1期14-17,共4页
Adverse Drug Reactions Journal
